Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase I trial of LY01008 (recombinant anti-VEGF humanized monoclonal antibody) compared with Avastin

Next Previous
X
Search
Trial Profile

Phase I trial of LY01008 (recombinant anti-VEGF humanized monoclonal antibody) compared with Avastin

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 12 May 2021

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Bevacizumab (Primary)
  • Indications Colorectal cancer; Non-small cell lung cancer
  • Focus Adverse reactions

    • Most Recent Events

    • 07 May 2021 According to a Luye Pharma Group media release, LY01008 (Bevacizumab injection), has received marketing authorization from China's National Medical Products Administration (NMPA), for the treatment of advanced, metastatic or recurrent non-small-cell lung cancer (NSCLC), and metastatic colorectal cancer.
    • 20 Apr 2020 According to a Luye Pharma Group media release, marketing authorization application for the LY01008 (Bevacizumab injection), has been accepted by the China Center for Drug Evaluation of National Medical Products Administration. The application was based on clinical data from two comparative studies with Avastin, the first a PK study in healthy subjects, the second a comparative study of efficacy and safety in metastatic or recurrent non-squamous non-small-cell lung cancer patients.
    • 21 Aug 2017 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top